A Phase I, Randomised, Open-Label, Single-Dose, Two-Treatment, Two-Way Crossover, Two-Stage Study to Evaluate the Bioequivalence of Onivyde (Irinotecan Liposome Injection) Manufactured at Two Different Sites Administered in Combination With Anti-Cancer Agents in Adult Participants With Metastatic Pancreatic Adenocarcinoma
Latest Information Update: 08 May 2025
At a glance
- Drugs Fluorouracil (Primary) ; Folinic acid (Primary) ; Irinotecan (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Pharmacokinetics
- Acronyms SIRACUSA
- Sponsors Ipsen
Most Recent Events
- 30 Apr 2025 Status changed from active, no longer recruiting to completed.
- 09 Apr 2025 Planned End Date changed from 3 Mar 2025 to 15 Apr 2025.
- 29 Jan 2025 Planned End Date changed from 6 Jan 2025 to 3 Mar 2025.